A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/3/2019
Start Date:March 25, 2019
End Date:March 31, 2024
Contact:Reference Study ID Number: GO40800 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. Only)

Use our guide to learn which trials are right for you!

A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety,
efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine
and daunorubicin in induction, in combination with cytarabine in consolidation, and as a
single agent in maintenance for treating participants with acute myeloid leukemia (AML).


Inclusion Criteria:

Inclusion Criteria for All Study Phases:

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2

- Adequate hepatic and renal function

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures, and agreement to refrain from
donating eggs with a failure rate of <1% per year during the treatment period and for
at least 6 months after the final dose of idasanutlin, cytarabine, or daunorubicin.
Women must refrain from donating eggs during this same period.

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive, measures, and agreement to refrain from donating sperm that together
result in a failure rate of <1% per year during the treatment period and for 6 months
after the final dose of idasanutlin, cytarabine, or daunorubicin. Men must refrain
from donating sperm during this same period.

Inclusion Criteria for Patients in the Dose-Escalation and Expansion Phases:

- Documented/confirmed newly diagnosed acute myeloid leukemia (AML) not previously treated
according to World Health Organization (WHO)

Inclusion Criteria for Patients in the Post-Consolidation Phase:

- Documented/confirmed AML according to WHO in remission after induction, within 21 days of
end of last chemotherapy consolidation cycle, and were minimum residual disease (MRD)
positive at the end of induction as per local laboratory assessment

Exclusion Criteria:

Exclusion Criteria for All Study Phases:

- Clinical evidence of central nervous system (CNS) leukemia

- Any Grade ≥2 non-hematologic toxicities prior to starting therapy

- Current treatment with any other investigational or commercial agents or therapies
administered with the intention to treat their malignancy with the exception of
hydroxyurea (HU) or 6-mercaptopurine (6-MP)

- Treatment-related AML

- Acute promyelocytic leukemia

- History of other malignancy that could affect compliance with the protocol or
interpretation of results

- Any severe and/or uncontrolled medical conditions or other conditions that could
affect their participation in the study, impair the ability of the investigator to
evaluate the patient, or impair the patient's ability to complete the study

- Echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan showing ejection
fraction ≤40%

- Non-malignant medical illnesses that are uncontrolled or whose control may be
jeopardized by this study treatment, such as hereditary coagulation disorders,
insulin-dependent diabetes mellitus not optimally controlled with medical management
(e.g., presence of ketoacidosis), or active GI conditions affecting absorption

- Infection considered by the investigator to be clinically uncontrolled or of
unacceptable risk to the patient upon the induction of neutropenia, that is, patients
who are or should be on antimicrobial agents for the treatment of active infection

- Febrile patients within 72 hours of study treatment initiation

- Patients with a history of active or chronic infectious hepatitis unless serology
demonstrates clearance of infection

- Patients who are unable to interrupt treatment with moderate to strong CYP2C8 inducers
and inhibitors

- Patients who are unable to temporarily interrupt treatment with oral or parenteral
anticoagulants/anti-platelet agents during treatment phase

- Patients who have a history of clinically significant liver cirrhosis

- Patients with extramedullary AML with no evidence of systemic involvement

- Pregnant or breastfeeding patients

- Known history of HIV-positive status

- Patients who might refuse to receive blood products and/or have a hypersensitivity to
blood products

- Prior treatment with an MDM2 antagonist

- Patients with clinically relevant QTc prolongation, a family history of long QT
syndrome

Exclusion Criteria for Patients in the Phase Ib Dose-Escalation Phase:

- Adverse risk patients as per European LeukemiaNet (ELN) 2017 criteria

Exclusion Criteria for Patients in Phase Ib Post-Consolidation Phase:

- Any ongoing Grade ≥2 hematologic adverse events prior to starting therapy

- Previous hematopoietic stem cell transplant (HSCT)

Exclusion Criteria for Patients in the Dose-Escalation Phase and Patients in the
Favorable/Intermediate-Risk Cohort of the Expansion Phase:

- Secondary AML, defined as AML evolving from antecedent hematologic disorder (AHD)
We found this trial at
14
sites
111 S 11th St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
675 N Saint Clair St # 21-100
Chicago, Illinois 60611
(312) 695-1156
Robert H. Lurie Comprehensive Cancer Center at Northwestern University The cancer center was first established...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Bedford Park, South Australia 5042
?
mi
from
Bedford Park,
Click here to add this to my saved trials
Brooklyn, New York 11203
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Fairway, KS
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials